Ultrastructural evidence for extravascular platelet recruitment in the lung upon intravenous injection of platelet-activating factor (PAF-acether) to guinea-pigs.

Bronchoconstriction and degenerative lesions of the bronchial epithelium were observed microscopically 1 min after the i.v. injection of 100 ng/kg of platelet-activating factor (PAF-acether) to the anaesthesized guinea-pig. Constricted arterioles containing marginated polymorphonuclear neutrophils and platelet aggregates were seen, as well as alveolar capillaries obstructed by thrombi formed by partially or totally degranulated platelets. Three minutes after the injection of PAF-acether, platelet diapedesis to the alveolar septa and lumen was clearly observed. Bronchoconstriction was still present at 3 min, but subsided after 60 min, whereas oedema of the submucosa persisted accompanied by an infiltration of eosinophils and neutrophils. The infusion of prostacyclin prevented the formation of platelet aggregates and platelet diapedesis due to PAF-acether, but the morphological evidence of bronchial constriction was not modified. Aspirin failed completely to modify the effects of PAF-acether. Our results show that PAF-acether causes early formation and deposition of platelet aggregates, accompanied by the margination of polymorphonuclear neutrophil leucocytes in pulmonary vessels of the guinea-pig. Since bronchoconstriction persisted when platelet aggregation was inhibited with prostacyclin, aggregation by itself would not account for this effect. Early platelet diapedesis in the vicinity of bronchial smooth muscle corroborates previous evidence that platelets contain and release bronchoconstrictor substances, which operate by cyclo-oxygenase-independent mechanisms and are possibly involved with the physiopathology of lung inflammation during immediate hypersensitivity.

[1]  M. Doni,et al.  Influence of the pure synthetic PAF (platelet aggregating factor) on clot retraction and platelet aggregation. , 2009, Scandinavian journal of haematology.

[2]  B. Vargaftig,et al.  The platelet‐independent release of thromboxane A2 by Paf‐acether from guinea‐pig lungs involves mechanisms distinct from those for leukotriene , 1984, British journal of pharmacology.

[3]  C. Page,et al.  Platelet‐activating factor: a possible mediator of the dual response to allergen? , 1984, Clinical allergy.

[4]  C. Page,et al.  Paf-acether: a mediator of inflammation and asthma , 1984 .

[5]  G. Smedegård,et al.  Acute microvascular effects of PAF-acether, as studied by intravital microscopy. , 1983, European journal of pharmacology.

[6]  C. Labat,et al.  The actions of Paf‐acether (platelet‐activating factor) on guinea‐pig isolated heart preparations , 1983, British journal of pharmacology.

[7]  B. Vargaftig,et al.  Non-steroidal anti-inflammatory drugs if combined with anti-histamine and anti-serotonin agents interfere with the bronchial and platelet effects of "platelet-activating factor" (PAF-acether). , 1982, European journal of pharmacology.

[8]  K. A. Knauer,et al.  Platelet activation during antigen-induced airway reactions in asthmatic subjects. , 1981, The New England journal of medicine.

[9]  G. Camussi,et al.  Mediators of immune-complex-induced aggregation of polymorphonuclear neutrophils. II. Platelet-activating factor as the effector substance of immune-induced aggregation. , 1981, International archives of allergy and applied immunology.

[10]  B. Vargaftig,et al.  Platelet-activating factor induces a platelet-dependent bronchoconstriction unrelated to the formation of prostaglandin derivatives. , 1980, European journal of pharmacology.

[11]  B. Vargaftig,et al.  The role of platelet-activating factor in platelet aggregation , 1979, Nature.

[12]  B. Vargaftig,et al.  ROLE OF PLATELETS IN ASPIRIN‐SENSITIVE BRONCHOCONSTRICTION IN THE GUINEA‐PIG; INTERACTIONS WITH SALICYLIC ACID , 1978, British journal of pharmacology.

[13]  E. Reynolds THE USE OF LEAD CITRATE AT HIGH pH AS AN ELECTRON-OPAQUE STAIN IN ELECTRON MICROSCOPY , 1963, The Journal of cell biology.